Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Michael G, Overstreet"'
Autor:
Jill Walker, Jane Osbourn, Arnaud C. Tiberghien, Nazzareno Dimasi, Dipesha P. Shah, Terrence O'Day, Steven Novick, William O. Iverson, Yuling Wu, Bo Zheng, Shannon Breen, Subramanya Karanth, Ryan Fleming, Agnieszka Sadowska, Christopher Ward, Vanessa Muniz-Medina, Suneetha B. Thomas, Elaine M. Hurt, Michael G. Overstreet, Saravanan Rajan, Ruoyan Chen
Multiple myeloma is a hematologic cancer that disrupts normal bone marrow function and has multiple lines of therapeutic options, but is incurable as patients ultimately relapse. We developed a novel antibody–drug conjugate (ADC) targeting CS-1, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::063a7b8839eda8429b31260763a0368a
https://doi.org/10.1158/1535-7163.c.6542664
https://doi.org/10.1158/1535-7163.c.6542664
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
Supplementary Materials and Methods, and Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238b4ab5c831dd6063dffdf564c8ad3c
https://doi.org/10.1158/2159-8290.22540037
https://doi.org/10.1158/2159-8290.22540037
Autor:
Jill Walker, Jane Osbourn, Arnaud C. Tiberghien, Nazzareno Dimasi, Dipesha P. Shah, Terrence O'Day, Steven Novick, William O. Iverson, Yuling Wu, Bo Zheng, Shannon Breen, Subramanya Karanth, Ryan Fleming, Agnieszka Sadowska, Christopher Ward, Vanessa Muniz-Medina, Suneetha B. Thomas, Elaine M. Hurt, Michael G. Overstreet, Saravanan Rajan, Ruoyan Chen
Supplementary Materials and Methods, Supplementary Table S1. Sources of cell lines and cell growth media; Supplemental Table S2. Sources of antibodies for flow cytometry; Supplementary Table S3. CS-1 ADC Characteristics, Supplemental Table S4. Pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62318dd34971780d373a1e55ed154426
https://doi.org/10.1158/1535-7163.22520520.v1
https://doi.org/10.1158/1535-7163.22520520.v1
Autor:
Yariv Mazor, Robert W. Wilkinson, Daniel J. Freeman, Ikbel Achour, William Dall'Acqua, Aleksandra D. Toloczko, Thomas V. Murray, Frances Neal, Gareth J. Browne, Godfrey J. Rainey, Michelle Morrow, Asis Palazon, Yanli Wu, James Dodgson, Michael G. Overstreet, Yaya Wang, Kathy Mulgrew, Stacy Kentner, Xiaofang Jin, Arthur Lewis, Kapil Vashisht, Shelby D. Gainer, Deepa S. Subramaniam, Ben Tran, Seock-Ah Im, Bo Wang, Sumati Hasani, Des C. Jones, James Hair, Anna Hansen, Lorraine Irving, Suzanne I. Sitnikova, Chunning Yang, Matthew J. Elder, Simon J. Dovedi
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ca7eaed273b219faf1bb63ec9cf8694
https://doi.org/10.1158/2159-8290.c.6549263
https://doi.org/10.1158/2159-8290.c.6549263
Autor:
Bo Wang, Frances Neal, Arthur Lewis, Kapil Vashisht, Deepa S. Subramaniam, Des C. Jones, Sumati Hasani, Daniel J. Freeman, Chunning Yang, Lorraine Irving, Michael G. Overstreet, Gareth J. Browne, Suzanne I. Sitnikova, James Hair, Robert W. Wilkinson, Yaya Wang, Ben Tran, Ikbel Achour, James Dodgson, Shelby D. Gainer, Xiaofang Jin, Seock-Ah Im, William F Dall'Acqua, Yariv Mazor, Godfrey Rainey, Asis Palazon, Anna Hansen, Yanli Wu, Matthew J. Elder, Stacy Kentner, Aleksandra D. Toloczko, Michelle Morrow, Murray Thomas Vincent, Simon J. Dovedi, Kathy Mulgrew
Publikováno v:
Cancer Discovery. 11:1100-1117
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent
Autor:
Simone Difilippantonio, Christina Robinson, Alexandra S Zimmer, Patricia S. Steeg, Debbie Wei, Michael G. Overstreet, Imran Khan, Brunilde Gril
Publikováno v:
Neuro Oncol
BackgroundBrain metastases of HER2+ breast cancer persist as a clinical challenge. Many therapeutics directed at human epidermal growth factor receptor 2 (HER2) are antibodies or antibody-drug conjugates (ADCs), and their permeability through the blo
Autor:
Nina J. Chu, Michael G. Overstreet, Ryan Gilbreth, Lori Clarke, Christina Gesse, Eric Tu, Gordon Moody, Maria Letizia Giardino Torchia
Publikováno v:
Cancer Research. 82:2837-2837
Background: Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the third leading cause of cancer-related death worldwide. Immune checkpoint inhibitors have been recently approved in the first-line setting, however only 20-30%
Autor:
Lori A. Clarke, Michael G. Overstreet, Eric Tu, Christina Gesse, Nina Chu, Letizia Giardino, Gordon Moody, Ryan Gilbreth
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Chimeric antigen receptors (CARs) are engineered synthetic receptors that reprogram T cell specificity and function against a given antigen. Autologous CAR-T cell therapy has demonstrated potent efficacy against various hematological malig
Autor:
Deepali Malhotra, Jill Walker, Ruoyan Chen, Jane K. Osbourn, Vanessa Muniz-Medina, James Kurasawa, Stacy Kentner, Gordon Moody, Michael G. Overstreet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background With the success of T cell checkpoint antagonists in treating cancer, we must better understand treatment response heterogeneity and develop more physiological preclinical models for evaluating the next wave of candidate therapeutics. Seve
Autor:
Simon J, Dovedi, Matthew J, Elder, Chunning, Yang, Suzanne I, Sitnikova, Lorraine, Irving, Anna, Hansen, James, Hair, Des C, Jones, Sumati, Hasani, Bo, Wang, Seock-Ah, Im, Ben, Tran, Deepa S, Subramaniam, Shelby D, Gainer, Kapil, Vashisht, Arthur, Lewis, Xiaofang, Jin, Stacy, Kentner, Kathy, Mulgrew, Yaya, Wang, Michael G, Overstreet, James, Dodgson, Yanli, Wu, Asis, Palazon, Michelle, Morrow, Godfrey J, Rainey, Gareth J, Browne, Frances, Neal, Thomas V, Murray, Aleksandra D, Toloczko, William, Dall'Acqua, Ikbel, Achour, Daniel J, Freeman, Robert W, Wilkinson, Yariv, Mazor
Publikováno v:
Cancer discovery. 11(5)
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a monovalent